top of page
Browse by category
Search


Obesity-related cancer rising among both younger and older adults worldwide
Researchers from The Institute of Cancer Research and Imperial College London have reported cancer incidence rates increased for several cancer, apart from colorectal cancer, increases occurred in both younger and older adults. The cancer types where incidence rates rose for both younger and older adults were all related to obesity. The researchers studied annual cancer incidence data from 2003 to 2017 from 42 countries in Asia, Europe, Africa, North and South America, and Au


Brain scans could predict future weight gain in people with mental disorders
A simple standard MRI brain scan could predict which people with mental illnesses will gain weight after their initial diagnosis, thereby increasing their risk of physical diseases, and which ones will not. Visualisation and performance of the BMI predictor. Credit: Nature Mental Health (2025). DOI: 10.1038/s44220-025-00522-3 "This would allow us to start targeted prevention against the weight gain frequently observed in this patient group," explained Professor Nikolaos Kouts


Sirona dual-polymer hydrogel aims to bridge gap in obesity treatments
Sirona - a dual-polymer hydrogel pill - could soon offer a new and affordable weight management treatment, following a successful clinical trial involving University of Bristol researchers. Sirona developed by Oxford Medical Products is a hydrogel-based pill that is designed to aid weight loss by reducing hunger. After it is swallowed, the pill expands in your stomach, making you feel full faster. This helps you eat less without needing strong medications or injections. In th


Ascletis completes enrolment in US study for once-monthly subcutaneous depot treatment GLP-1R agonist ASC30 for obesity
Ascletis Pharma has completed enrolment in the US Phase IIa study for its once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity. All 65 participants are obese or overweight with at least one weight-related comorbidity. The Phase IIa study of ASC30 once-monthly SQ depot treatment formulation is a 12-week, randomised, double-blind, placebo-controlled and multi-centre study co


FDA approves Novo Nordisk’s oral semaglutide (Rybelsus) for CV risk reduction in T2DM adults
Novo Nordisk has received FDA approval for Rybelsus for reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior CV event or not (primary and secondary prevention). Results of the SOUL trial reinforce the clinical profile of the semaglutide molecule, which has been studied across a variety of therapeutic areas. "Ev


Anti-obesity drug market expected to grow to $82.55 billion by 2032
The global anti-obesity drug market is estimated to increase in valve to $25.87 billion in 2025 and is expected to reach $82.55 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 18.01% from 2025 to 2032. This strong market growth is driven by the rising global prevalence of obesity and the increasing demand for effective pharmaceutical treatments, according to a re[ort by According to Coherent Market Insights (CMI). Additionally, advancements in drug formul


Factors influencing a patient's decision to undergo bariatric surgery
A patient’s decision to undergo bariatric surgery is often driven by a combination of complex factors such as health concerns, impaired quality of life and societal pressure, according to researchers from the University College Cork, Cork, Ireland. They found that health concerns were the primary motivator, with participants seeking to address comorbidities, mitigate health risks, and enhance their quality of life. In addition, body image, psychological well-being, and resist


Blood-based biomarkers could help predict adolescent bariatric surgery outcomes
Blood tests taken before bariatric surgery were associated with blood pressure readings five years later, according to a study from the Keck School of Medicine of USC and Ann & Robert H Lurie Children’s Hospital of Chicago. A USC-led team has developed an innovative way to predict blood pressure outcomes after bariatric surgery that outperforms the current standard practice. In 108 adolescents who underwent bariatric surgery, the researchers used blood tests taken before the


Download Bariatric News issue 56
Issue 56 of Bariatric News is now available to read and/or download. In this issue, we report gastric bypass associated with a lower incidence of MACE vs. sleeve gastrectomy over an 11-year follow-up, and the world’s first transcontinental bariatric robotic procedure. We also highlight a symposia from the IFSO-EC Congress that examined the considerations when moving from laparoscopic to robotic-assisted bariatric surgery, and have an exclusive interview with Mr Ahmed Ahmed ab


PapB peptides could help build next-generation GLP-1 drugs
Researchers at the University of Utah have uncovered an enzyme, PapB, that can ‘tie off’ therapeutic peptide into tight rings, a process known as macrocyclisation. This enzymatic trick could help drug developers make stronger, longer-lasting versions of GLP-1 medications. Graphic illustrates the PapB enzyme that ties off peptides (Credit: American Chemical Society and University of Utah) Creating cyclic peptides is valuable because these ring structures make drugs more stable
Browse by tag






bottom of page
